Elfabrio
pegunigalsidase alfa · Chiesi Farmaceutici S.p.A
AUTHORISED IN THE EUWhat Elfabrio is used for
Elfabrio is indicated for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease (deficiency of alpha-galactosidase).
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Elfabrio
- Active substance
- pegunigalsidase alfa
- Disease area
- Fabry Disease
- Medicine group
- Other alimentary tract and metabolism products
- ATC code
- A16AB20
- Marketing authorisation holder
- Chiesi Farmaceutici S.p.A
- Authorised in the EU since
- 2023
Official information
In the USA
Same active substance: Elfabrio
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Elfabrio used for?
Elfabrio is indicated for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease (deficiency of alpha-galactosidase).
What is the active substance in Elfabrio?
Elfabrio contains pegunigalsidase alfa.
Who makes Elfabrio?
The EU marketing authorisation holder is Chiesi Farmaceutici S.p.A.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU